Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco,
CA 94080
Phone: 650-624-1100
Fax: 650-624-1101
Web Site: http://www.rigel.com
| Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. The companys products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono. The company was founded in 1996 and is based in South San Francisco, California. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Mr. James M. Gower , 61
Chairman, Chief Exec. Officer, Pres and Chairman of Fin. Committee
|
N/A
|
N/A |
Dr. Donald G. Payan M.D., 61
Co-Founder, Pres of Discovery & Research
|
N/A
|
N/A |
Mr. Ryan D. Maynard , 40
Chief Financial Officer, Principal Accounting Officer and VP of Fin.
|
$
300.00K |
N/A |
Mr. Raul R. Rodriguez , 49
Chief Operating Officer and Exec. VP
|
N/A
|
N/A |
Dr. Elliott B. Grossbard M.D., 62
Chief Medical Officer and Exec. VP
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
